Showing 1 - 3 of 3 Hematologic Cancers
A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >

ASTX727 vs IV Decitabine in MDS and CMML

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remissi ... Read more >

Live Chat Available